- Home
- NVCR vs GHRS Comparison
NVCR vs GHRS Comparison
Compare NVCR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | GHRS |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Switzerland | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVCR | GHRS |
|---|---|---|
| Price | $14.70 | $20.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $26.86 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 1.2M | 275.1K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $655,353,000.00 | N/A |
| Revenue This Year | $10.80 | N/A |
| Revenue Next Year | $10.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.28 | N/A |
| 52 Week Low | $9.82 | $12.04 |
| 52 Week High | $21.45 | $31.44 |
Technical Indicators
Market Signals| Indicator | NVCR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 25.52 |
| Support Level | $13.12 | $19.75 |
| Resistance Level | $15.19 | $25.30 |
| Average True Range (ATR) | 0.62 | 1.38 |
| MACD | -0.12 | -0.37 |
| Stochastic Oscillator | 29.51 | 3.51 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.